• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Introduction to 6-(1-Butylpiperidin-2-yl)quinoline (CAS No. 1355225-87-4)

6-(1-Butylpiperidin-2-yl)quinoline, identified by the Chemical Abstracts Service Number (CAS No.) 1355225-87-4, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. This compound belongs to the quinoline class, which is well-documented for its broad spectrum of pharmacological effects, including antimicrobial, antimalarial, and anticancer properties. The structural motif of 6-(1-Butylpiperidin-2-yl)quinoline incorporates a piperidine ring linked to a quinoline core, which is a common scaffold in the development of drugs targeting central nervous system (CNS) disorders and other therapeutic areas.

The 1-butylpiperidin-2-yl substituent in the molecule introduces a lipophilic character, which can enhance the compound's ability to cross the blood-brain barrier (BBB). This feature is particularly crucial for drugs intended to act on neurological targets, as it improves their bioavailability and efficacy. The quinoline portion of the molecule is known for its ability to interact with various biological targets, including enzymes and receptors involved in disease pathways. The combination of these structural elements makes 6-(1-Butylpiperidin-2-yl)quinoline a promising candidate for further investigation in medicinal chemistry.

Recent advancements in computational chemistry and molecular modeling have allowed researchers to predict the binding affinity and interaction profiles of 6-(1-Butylpiperidin-2-yl)quinoline with potential biological targets. Studies have suggested that this compound may exhibit inhibitory activity against certain kinases and other enzymes implicated in cancer progression. Additionally, its structural similarity to known pharmacophores has prompted investigations into its potential use as a scaffold for developing novel therapeutics targeting neurodegenerative diseases such as Alzheimer's and Parkinson's.

The synthesis of 6-(1-Butylpiperidin-2-yl)quinoline involves multi-step organic reactions, typically starting from commercially available quinoline derivatives and piperidine precursors. The introduction of the butyl group at the 2-position of the piperidine ring requires precise control over reaction conditions to ensure high yield and purity. Advances in synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions, have streamlined the synthesis process, making it more efficient and scalable for further research and development.

In vitro studies have begun to explore the pharmacological profile of 6-(1-Butylpiperidin-2-yl)quinoline, focusing on its interactions with target proteins and cellular pathways. Preliminary results indicate that this compound may possess inhibitory effects on certain enzymes associated with inflammation and cell proliferation. These findings are particularly intriguing given the growing interest in targeting these pathways for therapeutic intervention in chronic diseases. Further research is needed to fully elucidate its mechanism of action and potential side effects.

The development of novel drug candidates like 6-(1-Butylpiperidin-2-yl)quinoline relies heavily on collaboration between synthetic chemists, pharmacologists, and bioinformaticians. By leveraging high-throughput screening technologies and machine learning algorithms, researchers can rapidly identify promising compounds and optimize their properties for clinical applications. The integration of experimental data with computational predictions has accelerated the drug discovery process significantly over recent years.

Regulatory considerations are also critical in advancing compounds like 6-(1-Butylpiperidin-2-yl)quinoline towards clinical trials. Compliance with Good Manufacturing Practices (GMP) ensures that synthesized materials meet stringent quality standards required for human testing. Additionally, toxicological assessments are essential to evaluate potential risks associated with long-term exposure to this compound.

The quinoline scaffold has a rich history in pharmaceutical development, with several approved drugs derived from this class demonstrating efficacy in treating various diseases. The structural diversity within quinolines allows for extensive modifications, making them versatile platforms for drug design. 6-(1-Butylpiperidin-2-yl)quinoline represents an example of how modifying existing scaffolds can lead to novel compounds with improved pharmacological properties.

Future directions for research on 6-(1-Anilino)-4-methoxyquinolinium chloride CAS No 1355225 87 4 CAS No 1355225 87 4 CAS No 1355225 87 4 include exploring its interactions with additional biological targets and evaluating its efficacy in preclinical models. Investigating analogs with different substituents on both the quinoline and piperidine moieties may reveal new insights into structure-function relationships within this class of compounds.

The broader impact of such research extends beyond individual compounds like 6-(1-Anilino)-4-methoxyquinolinium chloride CAS No 1355225 87 4 CAS No 1355225 87 4 CAS No 1355225 87 4, contributing to our fundamental understanding of disease mechanisms and accelerating the development of next-generation therapeutics. As computational tools become more sophisticated and high-throughput screening technologies advance, the pace at which novel drug candidates are identified is expected to increase significantly.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)